📣 VC round data is live. Check it out!

Navamedic Valuation Multiples

Discover revenue and EBITDA valuation multiples for Navamedic and similar public comparables like Nortech Systems, Rockwell Medical, Meditera, Prolight Diagnostics and more.

Navamedic Overview

About Navamedic

Navamedic ASA is a pharmaceutical company supplying hospitals and pharmacies with pharmaceutical and medical nutrition products. The company generates its revenue from the Nordic countries.


Founded

2002

HQ

Norway

Employees

42

Financials (LTM)

Revenue: $62M
EBITDA: $6M

EV

$63M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Navamedic Financials

Navamedic reported last 12-month revenue of $62M and EBITDA of $6M.

In the same LTM period, Navamedic generated $24M in gross profit, $6M in EBITDA, and had net loss of ($1M).

Revenue (LTM)


Navamedic P&L

In the most recent fiscal year, Navamedic reported revenue of $61M and EBITDA of $5M.

Navamedic is unprofitable as of last fiscal year, with gross margin of 39%, EBITDA margin of 8%, and net margin of (4%).

See analyst estimates for Navamedic
LTMLast FY202320242025202620272028
Revenue$62M$61M$55M$57M$61M
Gross Profit$24M$24M$22M$23M$24M
Gross Margin39%39%39%39%39%
EBITDA$6M$5M$3M$5M$3M
EBITDA Margin9%8%6%9%5%
EBIT Margin3%3%8%6%3%
Net Profit($1M)($3M)$357K($593K)($3M)
Net Margin(2%)(4%)1%(1%)(4%)
Net Debt—$16M———

Financial data powered by Morningstar, Inc.

Navamedic Stock Performance

Navamedic has current market cap of $47M, and enterprise value of $63M.

Market Cap Evolution


Navamedic's stock price is $1.96.

Navamedic share price decreased by 3.8% in the last 30 days, and by 13.3% in the last year.

Navamedic has an EPS (earnings per share) of $-0.11.

See more trading valuation data for Navamedic
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$63M$47M0.2%-3.8%-16.2%-13.3%$-0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Navamedic Valuation Multiples

Navamedic trades at 1.0x EV/Revenue multiple, and 11.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Navamedic

EV / Revenue (LTM)


Navamedic Financial Valuation Multiples

As of May 26, 2026, Navamedic has market cap of $47M and EV of $63M.

Navamedic has a P/E ratio of (31.8x).

LTMLast FY202320242025202620272028
EV/Revenue1.0x1.0x1.1x1.1x1.0x
EV/EBITDA11.2x12.4x19.0x11.9x19.2x
EV/EBIT35.0x35.7x14.6x18.2x35.7x
EV/Gross Profit2.6x2.6x2.9x2.8x2.6x
P/E(31.8x)(18.5x)131.4x(79.1x)(18.4x)
EV/FCF(6.7x)25.0xn/m16.1x25.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Navamedic Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Navamedic Margins & Growth Rates

Navamedic grew revenue by 5% and EBITDA by 26% in the last fiscal year.

In the most recent fiscal year, Navamedic reported gross margin of 39%, EBITDA margin of 8%, and net margin of (4%).

See estimated margins and future growth rates for Navamedic

Navamedic Margins

Last FY202420252026202720282029
Gross Margin39%39%39%40%
EBITDA Margin8%9%5%10%
EBIT Margin3%6%3%3%
Net Margin(4%)(1%)(4%)0%
FCF Margin4%7%4%4%

Navamedic Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%4%6%5%
Gross Profit Growth7%5%5%7%
EBITDA Growth26%60%(38%)95%
EBIT Growth11%(20%)(49%)11%
Net Profit Growth(104%)(266%)329%(104%)
FCF Growth(5%)(189726%)(36%)(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Navamedic Operational KPIs

Navamedic's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $0.5M for the same period.

Navamedic's Rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Navamedic's Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Navamedic
LTMLast FY202320242025202620272028
Rule of 4018%15%———
Bessemer Rule of X32%23%———
Revenue per Employee—$1.5M———
Opex per Employee—$0.5M———
S&M Expenses to Revenue—8%9%9%8%
G&A Expenses to Revenue—3%2%2%3%
Opex to Revenue—36%31%33%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Navamedic Competitors

Navamedic competitors include Nortech Systems, Rockwell Medical, Meditera, Prolight Diagnostics, BPC Instruments, Jin Medical International, Viveo, iZafe Group, Ortivus and Farmaceutica Remedia.

Most Navamedic public comparables operate across Medical Supplies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Nortech Systems0.4x—22.3x—
Rockwell Medical0.3x0.3x64.2x24.1x
Meditera0.8x—11.7x—
Prolight Diagnostics——(4.4x)—
BPC Instruments1.7x—7.7x—
Jin Medical International0.4x—8.2x—
Viveo0.3x0.3x3.7x4.6x
iZafe Group26.9x—(14.3x)—

This data is available for Pro users. Sign up to see all Navamedic competitors and their valuation data.

Start Free Trial

Navamedic M&A Activity

Navamedic has acquired 3 companies to date.

Last acquisition by Navamedic was on June 23rd 2025. Navamedic acquired dne pharma for $21M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Navamedic

dne pharma
Sensidose
Impolin
Description
DNE Pharma is a biopharmaceutical company developing treatments for opioid addiction and substance use disorders. Its pipeline features novel pharmacotherapies targeting mu-opioid receptors to alleviate withdrawal symptoms, reduce cravings, and prevent relapse. The company advances candidates through preclinical studies and Phase I trials in partnership with contract research organizations. Headquartered in the United States, DNE Pharma collaborates with addiction specialists and regulatory agencies to address gaps in current therapies like methadone and buprenorphine. Launched to combat the opioid epidemic, it emphasizes patient-centric formulations for improved adherence and outcomes.
—
—
HQ CountryNorwaySwedenSweden
HQ City
Oslo
—
—
Deal Date23 Jun 202529 Mar 20235 May 2022
Valuation$21M$9M$5M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Navamedic acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Navamedic

When was Navamedic founded?Navamedic was founded in 2002.
Where is Navamedic headquartered?Navamedic is headquartered in Norway.
How many employees does Navamedic have?As of today, Navamedic has over 42 employees.
Is Navamedic publicly listed?Yes, Navamedic is a public company listed on Oslo Børs.
What is the stock symbol of Navamedic?Navamedic trades under NAVA ticker.
When did Navamedic go public?Navamedic went public in 2006.
Who are competitors of Navamedic?Navamedic main competitors include Nortech Systems, Rockwell Medical, Meditera, Prolight Diagnostics, BPC Instruments, Jin Medical International, Viveo, iZafe Group, Ortivus, Farmaceutica Remedia.
What is the current market cap of Navamedic?Navamedic's current market cap is $47M.
What is the current revenue of Navamedic?Navamedic's last 12 months revenue is $62M.
What is the current revenue growth of Navamedic?Navamedic revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Navamedic?Current revenue multiple of Navamedic is 1.0x.
Is Navamedic profitable?Yes, Navamedic is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Navamedic?Navamedic's last 12 months EBITDA is $6M.
What is Navamedic's EBITDA margin?Navamedic's last 12 months EBITDA margin is 9%.
What is the current EV/EBITDA multiple of Navamedic?Current EBITDA multiple of Navamedic is 11.2x.
What is the current FCF of Navamedic?Navamedic's last 12 months FCF is ($9M).
What is Navamedic's FCF margin?Navamedic's last 12 months FCF margin is (15%).
What is the current EV/FCF multiple of Navamedic?Current FCF multiple of Navamedic is (6.7x).
How many companies Navamedic has acquired to date?As of May 2026, Navamedic has acquired 3 companies.
What was the largest acquisition by Navamedic?$21M acquisition of dne pharma on 23rd June 2025 was the largest M&A Navamedic has done to date.
What companies Navamedic acquired?Navamedic acquired dne pharma, Sensidose, and Impolin.
In how many companies Navamedic has invested to date?Navamedic hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Navamedic

Lists including Navamedic

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial